RxDoctor Payments Data

Vincent Leddy, MD

Internal Medicine · Brentwood, NYNPI 1538201231

Payments from drug & device makers

$17,147in general payments, 2019–2025

Across 933 payments — averaging $18.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AstraZeneca$1K
  • Amgen$1K
  • AbbVie$1K
  • GSK$1K
  • Mannkind Corporation$834
  • plus $9K from 54 others

What the payments were for

  • Consulting fees$220%
  • Food & beverage$16,81698%
  • Education$3102%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk98$1,777
AstraZeneca88$1,431
Amgen(2 entities)62$1,201
AbbVie(2 entities)75$1,187
GSK58$1,133
Mannkind Corporation31$834
Lilly USA, LLC50$722
Novartis33$618
Regeneron Healthcare Solutions, Inc.28$578
Merck35$577
Johnson & Johnson(2 entities)29$492
Sanofi20$440
Astellas Pharma US Inc10$410
Xeris Pharmaceuticals, Inc.15$391
Amarin Pharma, Inc.20$356
Pfizer24$354
Redhill Biopharma Inc.18$323
Corcept Therapeutics16$308
Insulet Corporation15$257
Exact Sciences10$255
Sanofi-aventis U.S. LLC14$253
Dexcom, Inc.12$212
Teva Pharmaceuticals USA, Inc.13$208
Kowa Pharmaceuticals America, Inc.14$198
Esperion Therapeutics, Inc.11$184
Azurity Pharmaceuticals, Inc.10$183
Arbor Pharmaceuticals, Inc.9$175
Boehringer Ingelheim10$171
Intuity Medical Inc8$142
Antares Pharma, Inc.6$123
Intra-sana Laboratories5$115
Bayer5$111
Phadia US Inc.6$107
Takeda Pharmaceuticals U.S.A., Inc.7$93
Gilead5$90
Boston Scientific5$89
Abbott4$87
Biohaven Pharmaceuticals, Inc.4$83
Ardelyx, Inc.3$72
Daiichi Sankyo Inc.4$67
Clarus Therapeutics Inc.5$54
Acerus Pharmaceuticals Corporation3$52
Bardy Diagnostics, Inc.3$46
Renalytix AI, Inc.2$45
Bausch Health US, LLC3$45
Recordati_rare_diseases_inc.2$38
Intercept Pharmaceuticals, Inc.2$37
Alnylam Pharmaceuticals Inc.2$36
Cumberland Pharmaceuticals, Inc.2$33
Linus Health, Inc.1$30
Idorsia Pharmaceuticals US Inc1$24
Lundbeck LLC1$22
Baxter Healthcare1$22
Senseonics, Incorporated1$20
Biohaven Pharmaceutical Holding Company Ltd.1$20
Circassia Inc.1$19
Pacira Therapeutics, Inc.1$19
Verity Pharmaceuticals Inc.1$19
Exeltis, USA Inc.1$19
Halozyme Inc1$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,147 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$183,784
Medicare patients
139
Services billed
5,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide152$158,127
OzempicSemaglutide156$144,106
Diclofenac Sodium74$64,569
TrulicityDulaglutide63$64,026
Repatha SureclickEvolocumab88$53,374
FarxigaDapagliflozin Propanediol48$48,131
RybelsusSemaglutide27$39,308
XareltoRivaroxaban29$32,631
Xigduo XrDapaglifloz Propaned/Metformin43$32,135
JardianceEmpagliflozin28$31,396
ProliaDenosumab12$19,687
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$19,664
LinzessLinaclotide28$17,504
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog40$14,689
Praluent PenAlirocumab24$10,905

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$722$222,153215 claims
Novo NordiskOzempic, Rybelsus$1,777$183,414183 claims
AstraZenecaFarxiga$1,431$48,13148 claims
Johnson & JohnsonXarelto$492$32,63129 claims
Boehringer IngelheimJardiance$171$31,39628 claims
GSKTrelegy Ellipta, Breo Ellipta$1,133$28,71044 claims
AmgenProlia$1,201$19,68712 claims
AbbVieLinzess$1,187$17,50428 claims
PfizerEliquis$354$9,83617 claims
Arbor Pharmaceuticals, Inc.Edarbi$175$7,97120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brentwood

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →